RCS - ValiRx PLC - Shareholder Communications and Investor Webinar

ValiRxAnnouncement

06/12/2022 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221206:nRSF6670Ia&default-theme=true

RNS Number : 6670I  ValiRx PLC  06 December 2022

6 December 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Shareholder Communications and Investor Webinar

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, announces an update
regarding shareholder communications.

We are pleased to invite shareholders to join us for a Live Webinar Q&A on
13 December 2022 at 2pm where members of the Board will be available to answer
questions.  The webinar will be hosted via the BRR Media platform with
registration details posted on our website closer to the event.

We would like to thank Dr Adam Hargreaves for acting in the role of
Shareholder Representative over the past three months.  This trial period to
assess benefits to both the Company and to shareholders has now concluded and
we have mutually agreed to discontinue the role going forwards.

ValiRx CEO, Dr Suzy Dilly commented "I look forward to meeting shareholders in
our webinar and will endeavour to answer questions and concerns as fully as
possible.

I would particularly like to extend my appreciation to Adam for the time and
effort he has contributed over the past three months in the Shareholder
Representative role.  It has been a useful experience for us, however, the
regulatory constraints and commercial sensitivity around sharing information
led us to reconsider the value of this initiative and to concentrate on our
previous shareholder communication channels."

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                          Tel: +44 (0) 2476 796496

                                                     www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                               Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                      +44 (0) 115 787 0206

                                                     www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                 lucy@vformation.biz

                                                     sue@vformation.biz
 Cenkos Securities plc (Joint Broker)                Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)              Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZMGZNKZGZZM